{"id":"NCT00529152","sponsor":"ApoPharma","briefTitle":"Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients","officialTitle":"A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2007-09-14","resultsPosted":"2009-08-12","lastUpdate":"2009-09-02"},"enrollment":100,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Overload"],"interventions":[{"type":"DRUG","name":"Deferiprone","otherNames":["Ferriprox Oral Solution"]}],"arms":[{"label":"A","type":"OTHER"}],"summary":"* The primary objective is to assess the safety of Ferriprox oral solution for the treatment of iron overload in pediatric patients with transfusion-dependent anemia.\n* The secondary objective is to assess the efficacy of Ferriprox oral solution in reducing iron overload in pediatric patients with transfusion-dependent anemia.","primaryOutcome":{"measure":"Occurrence of Adverse Events","timeFrame":"24 Weeks","effectByArm":[{"arm":"Ferriprox Oral Solution","deltaMin":212,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":4,"countries":["Egypt","Indonesia","Malaysia"]},"refs":{"pmids":["20921906"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}